Barriers to obtaining gene expression profiling tests heightened their perceived importance among patients with early breast cancer who were deciding whether to have chemotherapy, a new study says. Gene expression profiling tests, such as Oncotype Dx, analyze the patterns of 21 different genes within cancer cells to help predict how likely it is that a women’s cancer will recur within 10 years after initial treatment and how beneficial chemotherapy will be to her.